Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are pitted against each other, but only one can be my preferred healthcare stock. Where to invest $1,000 right now? Our analyst team just revealed ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Eli Lilly (NYSE: LLY) is encouraged by trial data for its latest weight-loss and diabetes medications. Where to invest $1,000 ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

The Tobias-Lechleiter Institute for Clinical Innovation will serve as a hub for "groundbreaking" disease detection and ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...